Stacey N H, Cox J, Loblay R, Crosbie J
National Institute of Occupational Health & Safety, University of Sydney, NSW, Australia.
Exp Hematol. 1989 Mar;17(3):273-7.
Treatment of murine CBA splenocytes with Vibrio cholerae neuraminidase (VCN) prior to engraftment into cyclophosphamide (CY) immunosuppressed Balb/c x CBA mice reduced the incidence of acute lethal graft-versus-host disease (GvHD) and delayed mortality in the later phase of the disease. In the same model, pretreatment of donor splenocytes with VCN also reduced splenomegaly. Engraftment of F1 mice with CBA cells was clearly demonstrated at day 30 after infusion. Treatment of spleen cells with VCN did not compromise their ability to protect mice against irradiation-induced lethality. Furthermore, enzyme treatment was found to have no adverse effects on helper (TH-) and B-cell activity or on suppressor (TS-)cell function in adoptive transfer assays. Therefore, whereas the mechanism of the effect of the VCN preparation remains to be established, it is clear that the treatment provides protection against GvHD.
在将小鼠CBA脾细胞移植到经环磷酰胺（CY）免疫抑制的Balb/c×CBA小鼠体内之前，用霍乱弧菌神经氨酸酶（VCN）处理可降低急性致死性移植物抗宿主病（GvHD）的发生率，并延缓疾病后期的死亡率。在同一模型中，用VCN预处理供体脾细胞也可减轻脾肿大。输注后30天清楚地证明了F1小鼠与CBA细胞的移植。用VCN处理脾细胞不会损害它们保护小鼠免受辐射致死的能力。此外，在过继转移试验中发现酶处理对辅助性（TH-）和B细胞活性或抑制性（TS-）细胞功能没有不利影响。因此，虽然VCN制剂的作用机制尚待确定，但很明显这种处理可提供针对GvHD的保护作用。
